IMPACT OF METABOLIC AND CARDIOVASCULAR DISEASES ON THE COURSE OF COVID-19
Keywords:
COVID-19, SARS-CoV-2, hypertension, diabetes mellitus, cardiovascular disease.Abstract
The article describes the impact of cardio-metabolic comorbidities on the severity and course of COVID-19. A total of 116 patients were included in the study. The highest risk of developing critical or fatal COVID-19 disease was in patients with underlying cardiovascular disease [OR: 3.44, 95% CI: 2.65–4.48], followed by chronic lung disease, hypertension, and diabetes mellitus. Of the total cases, 64% had one of four comorbidities (diabetes, hypertension, chronic lung disease, or cardiovascular disease), the most common being hypertension, with a combined prevalence of 27%. The presence of comorbidities such as cardiovascular disease, chronic lung disease, hypertension, and diabetes mellitus resulted in a higher risk of developing critical or fatal COVID-19 disease, with the highest risk occurring with underlying cardiovascular disease.
References
Anderson R.M., Fraser C., Ghani A.C., Donnelly C.A., Riley S., Ferguson N.M., et al. Epidemiology, transmission dynamics and control of SARS: the 2002-2003 epidemic. Philos Trans R Soc Lond B Biol Sci. 2004 Jul 29;359(1447):1091–1105.
Al-Omari A., Rabaan A.A., Salih S., Al-Tawfiq J.A., Memish Z.A. MERS coronavirus outbreak: implications for emerging viral infections. Diagn Microbiol Infect Dis. 2019 Mar;93(3):265–285.
Dhama K., Khan S., Tiwari R., Sircar S., Bhat S., Malik Y.S., et al. Coronavirus disease 2019-COVID-19. Clin Microbiol Rev. 2020 Sep 16;33(4)
García L.F. Immune response, inflammation, and the clinical spectrum of COVID-19. Front Immunol. 2020; 11:1441.
Yang X., Yu Y., Xu J., Shu H., Xia J., Liu H., et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020 May;8(5):475–481.
website cdc Centers for Disease Control and Prevention People who are at higher risk for severe illness. https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-at-higher-risk.html Accessed on.
Wu C., Chen X., Cai Y., Xia J., Zhou X., Xu S., et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in wuhan, China. JAMA Intern Med. 2020 Jul 1;180(7):934–943.
Mills K.T., Stefanescu A., He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020 Apr;16(4):223–237.
Khan M.A.B., Hashim M.J., King J.K., Govender R.D., Mustafa H., Al Kaabi J. Epidemiology of type 2 diabetes - global burden of disease and forecasted trends. J Epidemiol Glob Health. 2020 Mar;10(1):107–111.
Guo W., Li M., Dong Y., Zhou H., Zhang Z., Tian C., et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev. 2020 Mar 31:e3319.
Hodgson K., Morris J., Bridson T., Govan B., Rush C., Ketheesan N. Immunological mechanisms contributing to the double burden of diabetes and intracellular bacterial infections. Immunology. 2015 Feb;144(2):171–185.
Guzmán-Flores J.M., López-Briones S. [Cells of innate and adaptive immunity in type 2 diabetes and obesity] Gac Med Mex. 2012 Aug;148(4):381–389.
Shu C.J., Benoist C., Mathis D. The immune system's involvement in obesity-driven type 2 diabetes. Semin Immunol. 2012 Dec;24(6):436–442.
Nishiga M., Wang D.W., Han Y., Lewis D.B., Wu J.C. COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. Nat Rev Cardiol. 2020 Sep;17(9):543–558.
Fried J.A., Ramasubbu K., Bhatt R., Topkara V.K., Clerkin K.J., Horn E., et al. The variety of cardiovascular presentations of COVID-19. Circulation. 2020 Jun 9;141(23):1930–1936.
Wark P.A.B., Johnston S.L., Bucchieri F., Powell R., Puddicombe S., Laza-Stanca V., et al. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J Exp Med. 2005 Mar 21;201(6):937–947.
Contoli M., Message S.D., Laza-Stanca V., Edwards M.R., Wark P.A.B., Bartlett N.W., et al. Role of deficient type III interferon-lambda production in asthma exacerbations. Nat Med. 2006 Sep;12(9):1023–1026.
